Did the FDA Just Ban NMN Supplements? скачать в хорошем качестве

Did the FDA Just Ban NMN Supplements?

Nicotinamide mononucleotide, or NMN, is popular among longevity enthusiasts and biohackers who take it for its potential, but as yet unproven, longevity benefits. It has been used in supplements, but a recent action by the FDA has industry and the life extension community worried that it could now be banned. Reversing its own earlier decision, the FDA has informed an NMN manufacturer that the molecule can no longer be marketed as part of dietary supplements. Another company that is testing NMN as a drug probably contributed to the decision, which is not being enforced as of now. While NMN has been sold in some markets since at least 2014, it is a relative newcomer to the US. In the past two years, several companies have filed NDI notifications, and FDA did object to them on various grounds, mostly claiming that there is insufficient proof that NMN supplementation is safe. In the last few years new human NMN studies have been published, which might have alleviated FDA concerns. However, recently, the FDA changed course and declared that beta NMN cannot be marketed as a supplement due to it already being investigated as a drug. The FDA decision was based on a provision in the Dietary Supplement Health and Education Act of 1994 stating that a dietary supplement cannot contain an ingredient that has been “authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public”, unless the investigations began after the ingredient had been approved for use in supplements. The reason for the reversal is unknown, but as reported by Natural Products Insider, in December 2021, Metro International Biotech, a startup pharmaceutical company, wrote to the FDA: “As a company that has instituted publicly available clinical trials on beta NMN, we request that FDA take the preclusion provision seriously to protect the rights of companies that have spent significant time and research to develop drug products from competition from dietary supplements”. According to Insider, the FDA confirmed that it had considered Metro’s request. Metro International Biotech, co-founded by David Sinclair, is targeting several diseases with NAD precursors. It has developed a proprietary version of beta NMN called MIB-626 and asked the FDA to approve its investigation as an investigational new drug. The FDA can decide whether to enforce its own rulings on supplements. In a notable example, NAC was excluded from the definition of a dietary supplement on similar grounds in 2021, but several months later, in response to an outcry that included citizen petitions and litigation, the FDA decided to exercise enforcement discretion with regard to NAC, effectively leaving its manufacturers alone for now. Currently, there is no sign of any NMN-containing supplements being taken off the shelves, and it is not clear whether the FDA will ultimately choose to enforce its ruling. Manufacturers of NMN supplements will likely continue pressing the FDA to exercise enforcement discretion, with Metro Biotech pulling in the opposite direction. FOOTAGE, IMAGES, AND MUSIC CREDITS ⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺ Music: "Elastic Vibe" by Ziv Moran PRODUCTION CREDITS ⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺ Host, Producer & Editor - Ryan O’Shea Writer - Arkadi Mazin Art - Mattijs Vonk, Tim Maupin Executive Producer - Keith Comito #NMN #NAD #Longevity #Health